Fig. 5

High TRF2 levels in TNBC patients correlate with a better response to neoadjuvant taxane-based therapy. a Representative IHC images of TRF2 score in tumor specimens retrieved from TNBC patients before neoadjuvant therapy. Scale bar: 30 µm. b TRF2-IRS distribution by patients’ response to taxane-based neoadjuvant therapy. Responders showed TRF2 IRS values significantly higher than no responders (Mann-Whitney test, p=0.010). c Analysis of TRF2 IRS value pre- and post- neoadjuvant taxane-based therapy. Post treatment TRF2-IRS values were significantly lower than pre-treatment (Wilcoxon test, p=0.005). d Kaplan-Meier EFS curves of TNBC patients subjected to neoadjuvant taxane-based therapy. Patients with TRF2 IRS^High had a longer time without disease recurrence than those with TRF2^Low (TRF2 IRS^High median time not estimable vs TRF2^Low median time 37 months 95%CI [4.7- 49.3], Log-rank test, p=0.005).